Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:23:04.866Z.
Calculation as of: 2026-10-06T18:23:04.866Z.
Quote observation: 2026-10-06T18:15:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e70a31ba84f000c4f33ebb31a0a06a86ed13fe2ad2db34235caa158b2a7ba390
PE RATIO
N/A
Market Cap
$1.48M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | $1.81M | N/A | N/A | N/A | N/A |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Beyond Air, Inc. (XAIR)vs › | $1.89M | N/A | N/A | N/A | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.92M | N/A | N/A | N/A | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.63M | N/A | 4.04 | 4.04 | 4.04 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.48M | N/A | N/A | N/A | N/A |
| PMGC Holdings Inc. (ELAB)vs › | $1.47M | N/A | N/A | N/A | N/A |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.17M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.74
Forward EPS (Est.)
$-21.00
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
